Biopharmaceutical
NIIMBL’s Viral Vector Program has selected eight teams to participate in an interlaboratory study focused on improving the accuracy of AAV9 capsid titer measurements. The goal is to enhance consistency in manufacture of gene therapy products.
The selected teams are:
- Carnegie Mellon University
- Keck Graduate Institute
- Landmark Bio
- Michigan Technological University
- MilliporeSigma
- North Carolina State University
- PATH Center for Vaccine Innovation & Access
- University of Delaware
Each team will evaluate United States Pharmacopeia’s (USP) new AAV9 reference material to assess its suitability as a universal calibrant.